Floatz logo

Ibandronate

Metastatic Malignant Neoplasm

Kelly Fitzgerald, MDSmall moleculePhase 3Active
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
56/ 100
Competitive Position
73/ 100

Competitive context

272 Active assets in the Metastatic Malignant Neoplasm cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
I-Mab Biopharma US Limited
Phase 3BB
Irinotecan
Incyte Corporation
Phase 3BB
Nivestim
Mayo Clinic
Phase 3BB
Cyclophosphamide
InSilico Medicine Hong Kong Limited
Phase 2/3BB
Pembrolizumab
InSilico Medicine Hong Kong Limited
Phase 2/3BB

View all 50 →

Same molecule, other indications

Ibandronate is also rated in:

metastatic carcinoma in the boneActive
BBB
Indicative · Phase 4
79 / 100
View asset →
breast cancerDormant
B
Indicative · Phase 3
62 / 100
View asset →
cirrhosis of liverActive
B
Indicative · Phase 4
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →